| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df874e3cf88adba3792dc9d5b5776180
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-706 |
| filingDate |
2009-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3046098098b9b67f2285ea0aa5d8b6eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31c5eed4f9f8e33b7c1c30d5ca60d5ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1239884cdd19b0a3a12c244ec79f8a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e08035b8380cb9c112a7ae82b8a89b03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_362d2c8fc84add1cc926655680700c1d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2e13c0b2158c77bfc29d50a4ad6be7e |
| publicationDate |
2011-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011263523-A1 |
| titleOfInvention |
Tet2 as a new diagnostic and pronostic marker in hematopoietic neoplasms |
| abstract |
The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017070189-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023020697-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11788144-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9297046-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012302517-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11015223-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108699598-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014183122-A1 |
| priorityDate |
2008-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |